These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
222 related items for PubMed ID: 31594446
21. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. Wei XW, Gao X, Zhang XC, Yang JJ, Chen ZH, Wu YL, Zhou Q. Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971 [Abstract] [Full Text] [Related]
30. Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination. Lee PH, Ou WF, Huang YH, Hsu KH, Tseng JS, Chang GC, Yang TY. Int J Mol Sci; 2024 Jun 25; 25(13):. PubMed ID: 39000058 [Abstract] [Full Text] [Related]
33. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options. Jurmeister P, Vollbrecht C, Behnke A, Frost N, Arnold A, Treue D, Rückert JC, Neudecker J, Schweizer L, Klauschen F, Horst D, Hummel M, Dietel M, von Laffert M. Lung Cancer; 2019 Dec 25; 138():43-51. PubMed ID: 31634654 [Abstract] [Full Text] [Related]
34. Lymph node metastasis in early invasive lung adenocarcinoma: Prediction model establishment and validation based on genomic profiling and clinicopathologic characteristics. Guo W, Lu T, Song Y, Li A, Feng X, Han D, Cao Y, Sun D, Gong X, Li C, Jin R, Du H, Chen K, Xiang J, Hang J, Chen G, Li H. Cancer Med; 2024 Jul 25; 13(14):e70039. PubMed ID: 39046176 [Abstract] [Full Text] [Related]
37. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK. Lung Cancer; 2014 Aug 25; 85(2):161-7. PubMed ID: 24857785 [Abstract] [Full Text] [Related]
38. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung. Chan AW, Chau SL, Tong JH, Chow C, Kwan JSH, Chung LY, Lung RW, Tong CY, Tin EK, Law PP, Law WT, Ng CSH, Wan IYP, Mok TSK, To KF. J Thorac Oncol; 2019 Jul 25; 14(7):1213-1222. PubMed ID: 30978501 [Abstract] [Full Text] [Related]
39. [THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER]. Belilovski Rozenblum A, Ilouze M, Dudnik E, Soussan-Gutman L, Dvir A, Peled N. Harefuah; 2017 Nov 25; 156(11):686-691. PubMed ID: 29198084 [Abstract] [Full Text] [Related]
40. Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations. Geng H, Li S, Guo Y, Yan F, Han Y, Xu M, Cui Y. Cancer Biomark; 2020 Nov 25; 27(4):525-532. PubMed ID: 32083571 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]